SAN DIEGO – The rapidly expanding therapeutic landscape of glucagon-like peptide-1 (GLP-1) receptor agonists, widely recognized for their transformative impact…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
GLP-1 Receptor Agonists and the Emerging Question of Anticancer Effects
The rapidly expanding landscape of drugs designed to mimic glucagon-like peptide-1 (GLP-1), famously exemplified by Ozempic and Wegovy, is increasingly…
Read MoreYOU MAY HAVE MISSED
